Double Medical Technology (002901) Fundamentals 2026 — P/E 27.7x, Revenue Analysis | SniperIQ
Double Medical Technology (002901) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥18.2B, trading at ¥43.84 on the SHZ. This SniperIQ fundamentals page covers Double Medical Technology's valuation (P/E 27.7x, P/B 4.8x), profitability (net margin 23.9%), revenue (¥2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Double Medical Technology's market cap?
Double Medical Technology (002901) has a market capitalization of approximately ¥18.2B, trading at ¥43.84 on the SHZ. Market cap moves with the live share price.
What is Double Medical Technology's P/E ratio?
Double Medical Technology's trailing twelve-month P/E ratio is 27.7x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Double Medical Technology?
Double Medical Technology runs a net profit margin of 23.9%, a gross margin of 70.3%, and an operating margin of 26.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Double Medical Technology generate?
Double Medical Technology reported revenue of ¥2.6B for fiscal year 2025, with net income of ¥600M and earnings per share (EPS) of 1.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Double Medical Technology pay a dividend?
Double Medical Technology offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Double Medical Technology financially healthy?
Double Medical Technology carries a debt-to-equity ratio of 0.10x and a current ratio of 4.23x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Double Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Double Medical Technology (002901) the key facts are: market cap ¥18.2B, P/E 27.7x, revenue ¥2.6B, 52-week range 39.58-66.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Double Medical Technology's full fundamentals live
Get Double Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.